

# PDA Training Course Extractables & Leachables


01 June 2022

## Setting Up Extractable Studies: Do's and Don'ts

Dries Cardoen




# Extractables & Leachables



# Extractables & Leachables

What **DOES** come out (from the material) in the **drug product**?




WHY performing an extractables study as you are only interested in Leachables?




# Extractables & Leachables

What **DOES** come out (from the material) in the **drug product**?



Leachables!




= screening directly in drug product

# Extractables & Leachables




**Drug product**




**Screening**



**Compatible  
with drug  
product?**



**Interference?**




**Threshold?**

# Extractables & Leachables




**Drug product**




**Screening**



**Compatible  
with drug  
product?**



**Interference?**



**Threshold?**



**THE ANSWER: YOU NEED EXTRACTABLES DATA**

# Purpose of an Extraction Study

- Material characterization of the packaging components
- “Impurities profiling” of the materials
  - Identify as many compounds as possible
  - Identify “bad actors” in the materials
- Early risk evaluation: potential *patient exposure* to chemical entities
- Allows to establish leachables – extractable correlations
- In certain cases (more applicable to OINDP): Facilitates extractable specifications of acceptance criteria.
- Identify compounds that may need to be monitored as leachable
  - Toxicity
  - Concentration in the materials
  - Risk for migration

# Purpose of an Extraction Study

## USP <1663> Monograph

*“Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems”*

This is an **INFORMAL** monograph



## **PQRI** – Parenteral & Ophthalmic Drug Products

Product Quality Research Institute

Best Demonstrated Practice Recommendations:  
**Chemistry & Toxicology**

This is a **RECOMMENDATION**

*REMARK: In Some Cases, Reference to the ISO 10993-12 (Medical Devices) can be Made to Determine the Extraction Conditions prior to Analysis.*



# Purpose of an Extraction Study

These two documents are either **INFORMAL** or **RECOMMENDATIONS**

## Allow flexibility in design

What is the *intent*? => **Strategy** of testing


How to design the study for the envisioned intent? => **Tactics**

## However, justification is needed!


Both **identifying the necessity** for an extraction study, as well as **justifying the design**, is the responsibility of the holder of the NDA.

# Purpose of an Extraction Study

1. **LOW** Nr of extractables



2. **HIGH** Nr of extractables



## HOW CAN THIS BE HARMONIZED?

# Useful documentation prior to testing

## GENERAL INFORMATION

*Product Name, Product N<sup>o</sup>, Type, Manufacturer, Physical properties...*

## CERTIFICATES of compendial tests

*USP<381>, USP <87>, USP<88>, EP 3.2.9, JP<49>, ISO 8871*

## INGREDIENTS OF RUBBER/PLASTIC

*Very useful information, but this will not tell the complete E-story!!*

## EXTRACTABLES DATA FROM SUPPLIER

*Highest Level of information !*

*Check relevancy of technical and testing conditions!!*

# Design Space of an Extraction Study

**VARIABLES** that may/will have an impact on the study design of an extractables study

- The **classification & specific requirements** per drug product
  - Table 1 in FDA C/C-Guidance (1999)
  - Decision tree in the EMA-Guideline (2005)
- The **composition of the DP**, in contact with the C/C system
- The **type of contact** between the DP and the C/C system
  - Primary packaging
  - Secondary packaging (e.g. needle shield, label,...)
- The **types of materials** used in the manufacture of the C/C
  - E.g. rubber versus polyolefin for BFS
- The **knowledge on the composition** of materials (from vendor)
  - Additives, catalysts, oligomers, colorants,...
- The **use of the data**
  - Only for this particular application, or also for other DP?
- Packaging versus Manufacturing Equipment
  - **Dedicated session**

# DESIGN OF AN EXTRACTABLES STUDY: EXTRACTION




**Extraction Solvents**



**Polarity,...**

ACIDIC

ALKALINE



**pH**




**Extraction conditions**



**Time & Temperature**



autoclave



Reflux



Incubation (shaking)



**Extraction ratio**



**Guidelines**



**Filling volume**



**SELECT WORST CASE CONDITIONS REPRESENTATIVE FOR FINAL APPLICATION**


# USP <1663> “Generating the Extract”

## Extraction Solvents

### Chemical Nature of the Extracting Medium

**If: PURPOSE:** *simulating worst case EXT-profile*

- Look for Similar or Greater Extraction Propensity
- That gives Similar Qualitative and Quantitative EXT-profile
- **Use Drug Product Formulation**
  - May be complex or impractical
- **DPV/Placebo can be an Alternative**
  - REMARK: Extraction at High T with DP/DPV may lead to degradation (eg Polysorbate)



# Purpose of an Extraction Study

## Extraction Solvents

Perform E-study in Drug Product (Vehicle), suggested in:

FDA-Container/Closure Guidance (1999), (eg parenteral/Ophthalmic)

- If the extraction properties of the drug product vehicle may reasonably be expected to differ from that of water (e.g., due to high or low pH or due to a solubilizing excipient), then drug product should be used as the extracting medium.

EMA-Guideline - immediate packaging (2005)

stress conditions to increase the rate of extraction. The solvent used for extraction should have the same propensity to extract substances as the active substance/dosage form as appropriate. In the case of medicinal products the preferred solvent would be the medicinal product or placebo vehicle. The

# Purpose of an Extraction Study

## Extraction Solvents


**ADVANTAGE:** simulation of extractables behaviour in DP(V): **same extraction propensity!**

**DISADVANTAGE:** **Risk of missing** the presence of compounds  
- *Matrix interference of DP(V) (see previous slide)*

Risk of **misinterpretation of analytical data**  
- *DP(V) Matrix degradant may be misinterpreted as extractable!*

### Risk of underestimating the concentration of compounds

- *Extraction conditions – may potentially be too mild*
- *Difficult to select the right set of extraction conditions (e.g. Extraction time, temperature!)*





# USP <1663>: Generating the Extract

## Extraction Solvents

### REMARKS WHEN CONSIDERING SELECTING DP/DPV

BETTER ALTERNATIVE:

### SCREENING LEACHABLE STUDY

- Use DP in the final Container/Closure System, stored in Stability
- Consider it **as an extra "Solvent"** in your Extractables Assessment
- **Use same Screening Methodologies** as you would do in an EXT Study
- This accounts for
  - **Unexpected Leachables** (due to ageing of Material, Hydrolysis, Oxidation, **Migrants** from Sec, Tertiary Packaging...)
  - **Reactive Leachables** (eg with API, other ingredients...)
  - **Accurate Prediction** of the Nature of the Leachables, and their Expected Levels
  - However:
    - Typically **not an End Point** in the Evaluation
    - Only a **"One Point Assessment"**
    - **Not all DP** are Amenable to Screening

# USP <1663>: Generating the Extract

## Extraction Solvents

- ***If an Extraction Study needs a Simulating Solvent***

- *Establish and Justify Composition of Simulating Solvent*

- *Evaluate the PCHEM Properties of the Drug Product*

- *pH*

- *Polarity (Polar, versus Non-Polar, or Intermediate Polarity)*

- *Stabilizers*

- *Solubilizing Agents*

- *Buffers*

- *Lipid containing solutions*

- *Biotech (proteins, peptides, blood derived products)*

- *Chelating Agent*

- ...

REMARK: FOR EXTRACTION STUDIES: NOT IDEAL TO ONLY TAKE 1 EXTRACTION SOLVENT  
COULD BE CONSIDERED IF THE PURPOSE IS TO PERFORM A SIMULATION STUDY

# USP <1663>: Generating the Extract

## Extraction Solvents

- ***If an Extraction Study needs MULTIPLE Simulating Solvents***
  - *Each Addressing 1 “Mechanism” that is relevant to the Drug Product*
  - *Is Consistent with the Industry “Best Practices” for High Risk Dosage Forms.*

**REMARK: PQRI: proteins may be more efficient in solubilizing leachables due to abundance of both hydrophilic and hydrophobic sites\***

*In this case, an approach with multiple simulating solvents may be warranted.*

\* PQRI –PODP L/E Work Group: Outcomes and Practical Applications, D, Paskiet, Presentation at PEPTALK, 2016

# USP <1663>: Generating the Extract

## Extraction Solvents

***If: PURPOSE: Material Characterization (not a worst case EXT profile)***

- ***Use POWERFUL extraction Solvents***
  - *GOAL: to have an Efficient Quantitative & Qualitative Extraction*
  - *Powerful Extraction Solvents*
    - *Softening*
    - *Swelling*
    - *Dissolving*

### EXAMPLES OF POWERFUL SOLVENTS:


Dichloromethane, Hexane, Isopropanol, Ethanol ... Selection will also depend upon the Material




# USP <1663>: Generating the Extract

## Extraction Solvents


pH 2,5




pH 9,5




UPW/IPA 50/50



IPA



HEXANE



IS: Internal Standard for GC/MS

\*: Internal Standard for LC/MS (not used in this GC/MS evaluation)

**REMARK: Notice the Substantial “Visual” Difference in Extraction Profiles for the Different Extraction Solvents!**



# USP <1663>: Generating the Extract

## Extraction Solvents



- PODP best demonstrated practice **recommendations**

UPW pH 2.5 Acid extractables	UPW pH 9.5 Alcalinic extractables	UPW/IPA (50/50) Intermediate polarity	IPA →	Hexane Non-polar
------------------------------------	---	---	----------	---------------------

SIMULATION

MATERIAL  
CHARACTERIZATION  
&  
SIMULATION  
(NON AQUEUOUS DP)

Recommendations:


- It is not mandatory to always include these 5 solvents
- The solvents should be adjusted to the physico chemical properties of the DP
- Justifications!!

# USP <1663>: Generating the Extract


## Extraction Techniques

### Reflux or Soxhlet Extractions

- Similar Extraction yields
- Reflux has shown - in limited cases - to introduce artefacts in extraction profile
  - Degradation of extractables during Reflux could occur



- Soxhlet has more practical implications
  - Takes longer (24h) to have the same extraction yields as reflux (8h)
  - Safety implications in Lab (24h extraction)
  - Less practical for solvents with high boiling points
  - Less practical for aqueous extraction vehicles
  - Not to be used when *pH adjusted solvents or mixtures (e.g. IPA/UPW)* are used



# USP <1663>: Generating the Extract

## Extraction Techniques

### Sonication

- **Less exhaustive** than reflux & soxhlet (PQRI)
- However, it may be **less detrimental to certain materials**
- Often used as the extraction technique for **labels**
  - Avoids desintegration of label, while extracting most relevant compounds
- Difficult to control (see USP<1663>)

### Sealed vessel

- Closed vessel avoids loss of **VOLATILE Organic Compounds**
- Typically ISO 10993-12 Conditions can be Used (e.g. 50°C, 72h)
- In general, a **24h SV-extraction** at a temperature of **10°C below boiling point** is **equivalent in yields** to an **8h reflux** extraction



# USP <1663>: Generating the Extract

## Extraction Techniques

### Headspace enrichment

- *Direct analysis of the material* using Headspace GC/MS
- Complete profile of **VOLATILE Organic Compounds**
- **Water soluble** Compounds are **better detected**  
(often a problem for Headspace GC on aqueous extracts)

### “In Situ” extraction

- Container is filled with extraction solution, capped with closure and incubated.
- Allows “**one sided extraction**”
  - Coated rubbers
  - Sealing discs for cartridges
  - Multi-layer foils
- Better simulation, less exhaustive

# USP <1663>: Generating the Extract

## Extraction Conditions

Consideration for “In-Situ” Extractions:

- Static Extraction: Pharmaceutical Packaging
- Dynamic Conditions, often considered for Production Items
  - *Tubings*
  - *Filters*
  - *Pump systems (also for IV administrations)*
- Dynamic extraction is a better simulation if the contact between the components and the DP/DS is also dynamic,


# USP <1663>: Generating the Extract

## Extraction Time and Temperature

*USP<1663> “Generating the extract” section “Extraction time and temperature”*

The combination of extraction time and temperature establishes the magnitude of

the driving force and the degree to which equilibrium is achieved



Time and temperature are closely linked to the extraction technique that is used

# USP <1663>: Generating the Extract




## Extraction Time and Temperature

Typical temperature / time settings:

- **Reflux** with organic solvents:
  - Boiling temperature, 8 h
- **Soxhlet** with organic solvents:
  - Boiling temperature, 24 h
- **Sonication:**
  - Room temperature, ½ to 1h
- **Sealed vessel** and **“in situ” extraction:**
  - 50°C, 72 h (ISO 10993-12)
  - 24h below boiling point of extraction solvent = equivalent to 8h reflux
- **Headspace enrichment:**
  - 40 minutes, temperature is selected based on the type of material (from 70°C for LDPE up to 150° for rubbers / elastomeric material)
- **Dynamic Extractions:**
  - Extraction Conditions are determined based upon the conditions of use

# USP <1663>: Generating the Extract


## Extraction Time and Temperature



# USP <1663>: Generating the Extract

## Extraction Time and Temperature

Asymptotic extraction profile - exhaustive extractions:



PQRI-Example:

- Test article: sulphur cured elastomer
- Extraction: DCM – soxhlet

*CONCLUSION: Extraction conditions on the 'plateau'-regime (equilibrium)  
= "MAXIMUM RISK"*

# USP <1663>: Generating the Extract

## Extraction Stoichiometry

***Stoichiometry: physical mass/surface area to volume***

*Can be based on*

*Known chemical ingredients in a component/material*

*Safety based thresholds for DP leachables*

*Known sensitivities of the analytical instrumentation*

*Stoichiometry can be manipulated to produce a more concentrated extract*

*REMARK: beware of solubility of extractables in extraction medium when “back extrapolating” to original ratio’s!*

*Physical state can be altered (cut, ground, altered in size...)*

# USP <1663>: Generating the Extract

## Extraction Stoichiometry

- Try to stay as close as possible to the ratio's of the actual use of the container
  - E.g. A rubber plunger for a 10 mL PFS could be extracted at a ratio of 1 plunger per 10 mL of solvent
- For raw materials, a reasonable, broadly accepted ratio is 1g/10mL
- For certain container closure systems (e.g. LVP), the final AET levels that may need to be considered may have an impact on the extraction ratio's!

### Example

- For a 1 L bag (bag weighs 50g), Final AET in DP is at 1.5µg/L
- This means that for the extraction study, 1.5µg/Bag(50g) or 30µg/g needs to be attained
- With a ratio of 1bag in 1L, this AET cannot be attained
- Higher material-to-solvent ratios will need to be considered



What **CAN** come out of the **material**?

**PACKAGING/MATERIAL**



**Extraction Solvents**



**Extraction conditions**



**Extraction ratio**

**ANALYSES  
OF THE  
EXTRACTS**



# Analyses of the extracts


A **broad identification** in “First Pass” extractable studies requires:

1. A compound specific detector: **Mass Spectrometry**
2. A **database** to allow Identification based upon Mass Spectra
  - Commercial Databases for GC/MS: NIST, WILEY
  - Customized Databases



IDENTIFICATION  
IDENTIFICATION  
IDENTIFICATION  
IDENTIFICATION  
**IDENTIFICATION**  
**IDENTIFICATION**  
IDENTIFICATION  
IDENTIFICATION


# Analyses of the extracts



# Analyses of the extracts



**Identification**



**Screening**


*Trying to identify every single peak in a chromatogram*


# Analyses of the extracts


## SCREENING: HOW DOES IT WORK?




## IDENTIFICATION












**VOC**

**SVOC**

**NVOC**



HS-GC/MS  
**Screening**

GC/MS  
**Screening**

UPLC/MS  
**Screening**



ICP/OES  
ICP/MS

IC  
GF-AAS  
LC/UV ...

**EXTRACTABLES PROFILE: Potentially Leaching Compounds of Concern**


# EXTRACTABLES

- ### Identification
- Knowledge of material
  - What **CAN** come out




### Initial Toxicological Evaluation

Example:  
Cramer + Derek Nexus  
Toxicologist/ consultant  
Select Targets



### LEACHABLES

- What **DOES** come out in the drug product



# TIME FOR QUESTIONS

